Risperidone sustained-release - Indivior

Drug Profile

Risperidone sustained-release - Indivior

Alternative Names: Long-acting Risperidone - Indivior; PERSERIS; RBP 7000

Latest Information Update: 31 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Reckitt Benckiser Pharmaceuticals
  • Developer Indivior
  • Class Antidepressants; Antineoplastics; Antipsychotics; Behavioural disorder therapies; Isoxazoles; Piperidines; Pyrimidinones; Small molecules
  • Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Schizophrenia

Most Recent Events

  • 28 Jul 2018 Registered for Schizophrenia in USA (SC)
  • 25 Jul 2018 Indivior intends to launch Risperidone sustained release in USA in fourth quarter of 2018
  • 05 May 2018 Updated adverse events and efficacy results from the phase III trial in Schizophrenia presented at the 171st Annual Meeting of the American Psychiatric Association (APA-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top